X
TXG icon

Xponance’s 10x Genomics TXG Stock Holding History

Xponance’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$600K Buy
15,642
+964
+7% +$25.3K ﹤0.01% 1015
2026
Q1 		$312K Buy
+14,678
New +$293K ﹤0.01% 1250
2025
Q2 		– Sell
-12,010
Closed -$105K – 1541
2025
Q1 		$105K Buy
12,010
+1,778
+17% +$22.4K ﹤0.01% 1344
2024
Q4 		$147K Sell
10,232
-181
-2% -$2.86K ﹤0.01% 1324
2024
Q3 		$235K Buy
10,413
+200
+2% +$4.13K ﹤0.01% 1171
2024
Q2 		$199K Sell
10,213
-1,418
-12% -$37.1K ﹤0.01% 1182
2024
Q1 		$437K Sell
11,631
-484
-4% -$21.3K ﹤0.01% 981
2023
Q4 		$678K Sell
12,115
-945
-7% -$41.1K 0.01% 820
2023
Q3 		$539K Buy
13,060
+400
+3% +$20.8K 0.01% 861
2023
Q2 		$707K Buy
12,660
+989
+8% +$53.5K 0.01% 775
2023
Q1 		$651K Buy
11,671
+454
+4% +$21.2K 0.01% 817
2022
Q4 		$409K Buy
11,217
+1,138
+11% +$37.2K 0.01% 954
2022
Q3 		$287K Buy
10,079
+558
+6% +$21.3K 0.01% 1006
2022
Q2 		$431K Sell
9,521
-20
-0.2% -$1.04K 0.01% 914
2022
Q1 		$726K Sell
9,541
-61
-0.6% -$5.34K 0.01% 725
2021
Q4 		$1.43M Buy
9,602
+223
+2% +$34.2K 0.02% 479
2021
Q3 		$1.36M Sell
9,379
-396
-4% -$68K 0.03% 452
2021
Q2 		$1.91M Buy
9,775
+3,771
+63% +$682K 0.04% 380
2021
Q1 		$1.09M Buy
6,004
+100
+2% +$17.3K 0.02% 456
2020
Q4 		$836K Sell
5,904
-48
-0.8% -$6.96K 0.02% 519
2020
Q3 		$742K Buy
5,952
+325
+6% +$34.1K 0.02% 505
2020
Q2 		$503K Buy
+5,627
New +$438K 0.01% 604

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Xponance's TXG Position: Q2 2026 in Review

Xponance increased its 10x Genomics (TXG) stake by 6.6% in Q2 2026, buying an estimated $25.3K and bringing the position to 15,642 shares worth $600K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Xponance first reported a position in TXG in Q2 2020 and has held it in 22 quarters since. The position peaked at $1.91M in Q2 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Xponance held 15,642 shares of 10x Genomics worth $600K as of Q2 2026.
  • Xponance bought 964 10x Genomics shares in Q2 2026, an estimated $25.3K.
  • 10x Genomics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1015 holding.
  • Xponance first reported a position in 10x Genomics in Q2 2020 and has held it in 22 quarters since.
  • Xponance's 10x Genomics position peaked at $1.91M in Q2 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.